The ITA notifies baseball athlete Jean Herrera Malambo of an apparent anti-doping rule violation
The International Testing Agency (ITA), on behalf of World Baseball Softball Confederation (WBSC), reports that it has notified Colombian baseball athlete Jean Herrera Malambo of an adverse analytical finding (AAF) for stanozolol.
The ITA reports that a sample collected from Jean Herrera Malambo, a baseball athlete from Colombia, during an out-of-competition testing mission on 8 November 2025, has returned an AAF¹ for stanozolol metabolites.
Stanozolol is prohibited under the WADA Prohibited List as S1.1 Anabolic Androgenic Steroids. Stanozolol is prohibited at all times (in- and out-of-competition) and is a non-specified substance. Stanozolol may boost athletic ability by increasing muscle strength and mass and accelerating recovery.
The athlete has been informed of the case and has the right to request the analysis of the B-sample.
If the B-sample analysis is requested and confirms the result of the A-sample, the case will be considered as a confirmed anti-doping rule violation. If the B-sample analysis is not requested, the case will also go ahead as a confirmed anti-doping rule violation. The athlete will have the opportunity to present his explanations for the result.
Further, in accordance with the World Anti-Doping Code and article 7.4.1 of the WBSC anti-doping rules, a mandatory provisional suspension has been imposed on the athlete. The athlete has the right to challenge the provisional suspension and ask for its lifting.
Pursuant to the WBSC’s delegation of its anti-doping program to the ITA, the prosecution of the case is being handled entirely by the ITA. Given that the case is underway, there will be no further comments made.
The original press release can be found here: https://ita.sport/news/the-ita-notifies-baseball-athlete-jean-herrera-malambo-of-an-apparent-anti-doping-rule-violation/
